1358PFirst-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI - Husain, H; Martins, R G; Goldberg, S B (Ann Oncol, 2017)
, et al.